Women's Health News

RSS

Specific bacteria in the bladder may indicate who is more prone to recurrent UTIs

Researchers at The University of Texas at Dallas have identified specific bacteria in the bladder that may indicate which postmenopausal women are more susceptible to recurrent urinary tract infections (UTIs), and they found that estrogen may play a role in reducing that susceptibility.

13 Dec 2022

Study discovers link between a lesser-known hormone and lipid levels in midlife women

Step aside estrogen. Scientists at the University of Pittsburgh have discovered a predictor of blood lipid -; or cholesterol -; status for midlife women that may be key to understanding how hormone replacement therapy contributes to heart health.

12 Dec 2022

Immunogenicity of SARS-CoV-2 antibody response in immune naïve children and adults

Researchers compare the contribution of antibodies against the SARS-CoV-2 receptor binding domain in vaccinated and naturally infected adults and children.

12 Dec 2022

Severe COVID-19 causes aging-like changes in the human brain

Severe COVID-19 triggers aging-like changes in the brain's frontal cortex region that results in cognitive deficits.

11 Dec 2022

Discovery of biomarkers lays the groundwork for predicting preeclampsia

A discovery by Stanford School of Medicine researchers of biomarkers in the blood and urine of women with a dangerous complication of pregnancy could lead to a low-cost test to predict the condition.

9 Dec 2022

Study may allow patients with multiple breast lesions to consider breast-conserving therapy as treatment option

Patients with multiple tumors in the same breast who underwent a lumpectomy followed by radiation therapy had local recurrence rates comparable to those historically observed in patients with a single tumor, according to results from the ACOSOG Z11102 (Alliance) prospective phase II clinical trial, which were presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

9 Dec 2022

Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free survival compared with placebo plus fulvestrant in the phase III CAPItello-291 clinical trial, according to results presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

9 Dec 2022

POLAR gene profile predicts which patients may and may not benefit from radiation therapy after breast-conserving surgery

Patients with invasive breast cancer who had low scores on an investigational gene molecular signature had similar rates of local recurrence whether or not they received adjuvant radiation therapy after breast-conserving surgery, according to results of a meta-analysis presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

9 Dec 2022

Study finds disparities in breast cancer screening, treatment access for underserved communities

Barriers to breast cancer screening remain despite Medicaid expansion for preventive screening tests and implementation of patient navigation programs under the Affordable Care Act, with women from underserved communities experiencing disproportionately low rates of screening mammography, according to a study that was conducted by New York Medical College (NYMC) School of Medicine (SOM) faculty and students and recently published in BMC Women’s Health.

9 Dec 2022

Microbiomes in female reproductive tract linked to pregnancy following use of ART

Specific microbial profiles are associated with better conception rates from assisted reproductive technology.

9 Dec 2022

Vaping during pregnancy may give babies a greater propensity to develop pulmonary disease

Babies born to mothers who vape during pregnancy are at greater risk of developing pulmonary dysfunction, according to a new mouse study from The Ohio State University.

8 Dec 2022

Study reveals how the HOXA5 gene may work to suppress breast cancer formation

Researchers at the Johns Hopkins Kimmel Cancer Center have revealed how the gene HOXA5 may work to suppress formation of breast cancers.

8 Dec 2022

Estrogen replacement therapy may be a tool to mitigate delirium

Delirium is common among women with urinary tract infections (UTIs)-; especially those who have experienced menopause.

8 Dec 2022

Trial establishes the clinical utility of circulating tumor cell count as biomarker in breast cancer care

The use of circulating tumor cell (CTC) count to guide the choice between chemotherapy and endocrine therapy as first-line therapy for patients with metastatic, estrogen receptor (ER)-positive/HER2-negative breast cancer provided overall survival benefit, compared with physician's choice of treatment, according to data from the STIC CTC trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

8 Dec 2022

VirtaMed and CICE to announce partnership for gynecological endoscopy certification

...

From VirtaMed 8 Dec 2022

More states to consider extending postpartum Medicaid coverage beyond two months

Updated results on a new approach to treating advanced ER-positive/HER2-negative breast cancer

A UCLA Jonsson Comprehensive Cancer Center researcher and collaborators in a multicenter study will present updated results and plans for further research on a new approach to treating advanced ER-positive/HER2-negative breast cancer.

7 Dec 2022

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1), according to results from the phase III DESTINY-Breast02 trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

HIV transmission from mother to child can be stopped with modern antiviral drugs

Antiviral drugs almost completely reduce the risk of mothers passing on HIV infection to their children, even in a low-income country with a high HIV incidence such as Tanzania, according to a new study in The Lancet HIV by researchers from Karolinska Institutet.

7 Dec 2022

Women's Health News

Specific bacteria in the bladder may indicate who is more prone to recurrent UTIs

Study discovers link between a lesser-known hormone and lipid levels in midlife women

Immunogenicity of SARS-CoV-2 antibody response in immune naïve children and adults

Severe COVID-19 causes aging-like changes in the human brain

Discovery of biomarkers lays the groundwork for predicting preeclampsia

Study may allow patients with multiple breast lesions to consider breast-conserving therapy as treatment option

Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

POLAR gene profile predicts which patients may and may not benefit from radiation therapy after breast-conserving surgery

Study finds disparities in breast cancer screening, treatment access for underserved communities

Microbiomes in female reproductive tract linked to pregnancy following use of ART

Vaping during pregnancy may give babies a greater propensity to develop pulmonary disease

Study reveals how the HOXA5 gene may work to suppress breast cancer formation

Estrogen replacement therapy may be a tool to mitigate delirium

Trial establishes the clinical utility of circulating tumor cell count as biomarker in breast cancer care

VirtaMed and CICE to announce partnership for gynecological endoscopy certification

More states to consider extending postpartum Medicaid coverage beyond two months

Updated results on a new approach to treating advanced ER-positive/HER2-negative breast cancer

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

HIV transmission from mother to child can be stopped with modern antiviral drugs

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News